Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tofacitinib for Chronic Granulomatous Disease With Inflammatory Complications
NCT05104723Phase 2Completed
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Start
- Aug 2022
- Primary completion
- May 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of tofacitinib oral solution in chronic granulomatous disease (CGD), sponsored by National Institute of Allergy and Infectious Diseases. Started Aug 2022; status: completed.
02
Drugs
tofacitinib oral solution
03
Conditions
chronic granulomatous disease (CGD)
Beyond the preview
Go deeper on NCT05104723.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05104723.